Document:

EX-10.11

					
		  	Exhibit 10.11
			
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

 AMENDED AND RESTATED 

NONEXCLUSIVE LICENSE AGREEMENT 

FOR COVID-19 RELATED TECHNOLOGY 

This Amended and Restated Non-Exclusive License Agreement for Covid-19 Related
Technology (“Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Ocean Promise, Inc.
(“Ocean”), a wholly owned subsidiary of Ocean Biomedical, Inc. (“OBM”) and a corporation having a principal place of business at 19W060 Avenue LaTours OakBrook IL 60523 is effective on the March 3, 2021 (“Effective
Date”), and supersedes and replaces that certain Non-Exclusive License Agreement for Covid-19 Related Technology, dated June 25, 2020, by and between Stanford
and OBM (“Original Agreement”). 
  

	1.	 BACKGROUND 

Stanford has an assignment of inventions for therapeutic applications related to COVID-19. One is entitled “ANG 1-7 as a therapeutic for coronavirus” and the other one is entitled “Ulinastatin as a Therapeutic for Corona Virus”. Both were invented in the laboratory of Dr. Kevin Grimes and described in
Stanford Docket ([####]) and ([####]) respectively. The invention was made in the course of research supported by Stanford. Stanford is committed to facilitating broad and rapid access to technologies that have been developed by Stanford to address
the COVID-19 pandemic. Stanford also wants to ensure the affordability of any COVID-19 products going to uninsured patient populations and those in developing countries.

  

	2.	 DEFINITIONS 

Whenever used in this Agreement with an initial capital letter, the following terms, whether used in the singular or the plural, shall have the
meanings specified below. 
  

	2.1	 “Change of Control” means the following, as applied only to the entirety of that part of
Ocean’s business that exercises all of the rights granted under this Agreement: 

  

	 	  (A)	 acquisition of ownership—directly or indirectly, beneficially or of record—by any person or group
(within the meaning of the Exchange Act and the rules of the SEC or equivalent body under a different jurisdiction) of the capital stock of Ocean representing more than 35% of either the aggregate ordinary voting power or the aggregate equity value
represented by the issued and outstanding capital stock of Ocean; and/or 

  

	 	  (B)	 the sale of all or substantially all Ocean’s assets and/or business in one transaction or in a series of
related transactions. 

  

	2.2	 “Licensed Field of Use” means therapeutic applications for
COVID-19. 

  

	2.3	 “Licensed Patent” means Stanford’s rights in U.S. Patent Application, Serial Number
62/992,768 filed on March 20, 2020 and U.S. Patent Application, Serial Number 62/002,207 filed on March 30, 2020, any foreign patent application corresponding thereto, and any divisional, continuation, or reexamination application,
extension, and each patent that issues or reissues from any of these patent applications. Any claim of an unexpired Licensed Patent is presumed to be valid unless it has been held to be invalid by a final judgment of a court of competent
jurisdiction from which no appeal can be or is taken. “Licensed Patent” excludes any continuation-in-part (CIP) patent application or patent.

  
  

PAGE 1 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

	2.4	 “Licensed Product” means a product, method or service in the Licensed Field of Use, the
making, having made, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent. 

 

	2.5	 “Licensed Territory” means worldwide. 

 

	2.6	 “Net Sales” means all gross revenue derived by Ocean, its distributors or designees, from the
sale, transfer or other disposition of Licensed Product to an end user. Net Sales excludes the following items (but only as they pertain to the making, using, importing or selling of Licensed Products, are included in gross revenue, and are
separately billed): 

  

	 	  (A)	 import, export, excise and sales taxes, and custom duties, but only to the extent that these are not
subsequently reimbursed; 

  

	 	  (B)	 costs of insurance, packing, and transportation from the place of manufacture to the customer’s premises
or point of installation; 

  

	 	  (C)	 credit for returns, allowances, or trades. 

 

	2.7	 “Stanford Indemnitees” means Stanford, Stanford Health Care and Lucile Packard Children’s
Hospital at Stanford, and their respective trustees, officers, employees, students, agents, faculty, representatives, and volunteers. 

  

	3.	 GRANT 

  

	3.1	 Grant. Subject to the terms and conditions of this Agreement, Stanford grants Ocean a license to
Stanford’s rights in the Licensed Patent in the Licensed Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory. 

 

	3.2	 Nonexclusivity. The license is nonexclusive in the Licensed Field of Use beginning on the Effective Date
and ending one year after the Effective Date. As long as the COVID- 19 pandemic remains active, as determined by official statements of the World Health Organization, and assuming Ocean is meeting the milestone commitments of Section 6.1, Ocean
can receive an additional one-year extension to the term of the license with Stanford’s consent, such consent not to be unreasonably withheld if Ocean is diligently developing the Licensed Products as
demonstrated by a written report provided to Stanford along with a written request for an extension. Further, once the COVID-19 pandemic has ended, as determined by the World Health Organization, Stanford
will, to the extent legally able to do so, meet with Ocean and consider in good faith any requested extension to the license, including but not limited to a more complete set of commercial terms and diligence milestones. 

  
  

PAGE 2 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

	3.3	 Addressing Underserved Populations. Ocean agrees that Licensed Products will be offered for sale in non-OECD (Organization for Economic Co-operation and Development, https://www.oecd.org/about/) member countries, and to under-insured and
low-income populations in OECD countries at a price that is equal to Ocean’s actual cost to manufacture and distribute such Licensed Products. Stanford will not require any earned royalty payment for
these sales. 

  

	3.4	 Specific Exclusion. Stanford does not: 

 

	 	  (A)	 grant to Ocean any other licenses, implied or otherwise, to any patents or other rights of Stanford other than
those rights granted under Licensed Patent, regardless of whether the patents or other rights are dominant or subordinate to any Licensed Patent, or are required to exploit any Licensed Patent; 

 

	 	  (B)	 commit to Ocean to bring suit against third parties for infringement; and 

 

	 	  (C)	 agree to furnish to Ocean any technology or technological information or to provide Ocean with any assistance.

  

	4.	 SUBLICENSING 

Ocean may not grant sublicenses. 
  

	5.	 GOVERNMENT RIGHTS 

This Agreement is subject to Title 35 Sections 200-204 of the United States Code. Among other things,
these provisions provide the United States Government with nonexclusive rights in the Licensed Patent. Ocean will ensure all obligations of these provisions are met. 
  

	6.	 DILIGENCE 

  

	6.1	 Milestones. Because the invention is not yet commercially viable as of the Effective Date, Ocean will
diligently develop, manufacture, and sell Licensed Product and will diligently develop markets for Licensed Product. In addition, Ocean will initiate a Phase 2/3 or Phase 3 trial for ulinastatin or angiotensin
1-7 within 12 months after the Effective Date of this Agreement. 

  

	6.2	 Progress Report. Every ([####]) months after the Effective Date of this Agreement, Ocean will submit a
written report to Stanford covering the preceding period. The report will use the template of Appendix A and will include information sufficient to enable Stanford to satisfy reporting requirements of the U.S. Government and for Stanford to
ascertain progress by Ocean toward meeting this Agreement’s diligence requirements. Each report will describe, where relevant: Ocean’s progress toward commercialization of Licensed Product, including work completed, key scientific
discoveries, summary of work-in- progress, current schedule of anticipated events or milestones, market plans for 

introduction of Licensed Product, and significant corporate transactions involving Licensed Product. Ocean will specifically describe how each
Licensed Product is related to each Licensed Patent. 
  

	6.3	 Clinical Trial Notice. Ocean will notify the Stanford University Office of Technology Licensing prior to
commencing any clinical trials at Stanford. If Ocean does not notify Stanford University Office of Technology Licensing at least [####] days prior to enrolling the first patient in a clinical trial at Stanford, Ocean agrees that it will pay ([####])
to Stanford within 30 days of being invoiced. 

  
  

PAGE 3 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

	7.	 ROYALTIES 

  

	7.1	 Issue Fee, License Maintenance Fees and Earned Royalties. In view of the ongoing COVID-19 pandemic, and unless Ocean exceeds a gross margin of [####]% on Licensed Products in one or more OECD countries, as determined by GAAP accounting principles, the license will remain free of fees and
royalties. At such time as the gross margin on Licensed Product in any OECD country exceeds [####]% in a single calendar quarter, the parties will meet and determine appropriate additional financial consideration for Stanford, as well as the terms
associated with such consideration. 

  

	8.	 ACCOUNTING 

  

	8.1	 Accounting. Ocean will maintain records showing manufacture, importation, sale, and use of a Licensed
Product for [####] years from the date of sale of that Licensed Product. Records will include general-ledger records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and related
information in sufficient detail to enable Stanford to determine the royalties payable under this Agreement. 

  

	8.2	 Audit by Stanford. Ocean will allow Stanford or its designee to examine Ocean’s records to verify
payments made by Ocean under this Agreement. 

  

	9.	 EXCLUSIONS AND NEGATION OF WARRANTIES 

 

	9.1	 Negation of Warranties. Stanford provides Ocean the rights granted in this Agreement AS IS and WITH ALL
FAULTS. Stanford makes no representations and extends no warranties of any kind, either express or implied. Among other things, Stanford disclaims any express or implied warranty: 

 

	 	  (A)	 of merchantability, of fitness for a particular purpose; 

 

	 	  (B)	 of non-infringement; or 

 

	 	  (C)	 arising out of any course of dealing. 

  
  

PAGE 4 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

	9.2	 No Representation of Licensed Patent. Ocean also acknowledges that Stanford does not represent or
warrant: 

  

	 	  (A)	 the validity or scope of any Licensed Patent; or 

 

	 	  (B)	 that the exploitation of Licensed Patent will be successful. 

 

	10.	 INDEMNITY 

  

	10.1	 Indemnification. Ocean will indemnify, hold harmless, and defend all Stanford Indemnitees against any
claim of any kind arising out of or related to the exercise of any rights granted Ocean under this Agreement or the breach of this Agreement by Ocean. 

  

	10.2	 No Indirect Liability. Stanford is not liable for any special, consequential, lost profit, expectation,
punitive or other indirect damages in connection with any claim arising out of or related to this Agreement, whether grounded in tort (including negligence), strict liability, contract, or otherwise. 

 

	10.3	 Workers’ Compensation. Ocean will comply with all statutory workers’ compensation and
employers’ liability requirements for activities performed under this Agreement. 

  

	10.4	 Insurance. During the term of this Agreement, OBM, on behalf of Ocean as its parent entity, will
maintain Commercial General Liability Insurance with a reputable and financially secure insurance carrier to cover the activities of Ocean and its affiliates and sublicensees. The insurance will provide minimum limits of liability of $[####] per
occurrence and will include all Stanford Indemnitees as additional insureds. Prior to any use of a Licensed Product in or for humans, the insurance coverage will be increased to provide minimum limits of liability of $[####] per occurrence. Prior to
any clinical trial using the Licensed Product, the insurance will include Clinical Trial Insurance in addition to the increased minimum limits of liability of $[####] per occurrence. Prior to any offering for sale of Licensed Product by Ocean, or
its affiliates or sublicensees, the insurance will include Product Liability Insurance, and will have minimum limits of liability of $[####] per occurrence. Insurance must cover claims incurred, discovered, manifested, or made during or after the
expiration of this Agreement and must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within [####] days of the Effective Date of this Agreement, and for each instance in which the
coverage is changed as per the requirements above, Ocean will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. Ocean will provide to Stanford [####] days prior written notice of cancellation or
material change to this insurance coverage. Ocean will advise Stanford in writing that it maintains a combination of excess liability coverage (following form) over primary insurance for at least the minimum limits set forth above. All insurance of
Ocean will be primary coverage; insurance of Stanford Indemnitees will be excess and noncontributory. 

  
  

PAGE 5 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

	11.	 EXPORT 

Ocean and its affiliates will comply with all applicable United States laws and regulations controlling the export of licensed commodities and
technical data relating to this Agreement. (For the purpose of this paragraph, “licensed commodities” means any article, material or supply but does not include information; and “technical data” means tangible or intangible
technical information that is subject to U.S. export regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering designs and specifications, manuals and instructions.) These laws and regulations may include, but are not
limited to, the Export Administration Regulations (15 CFR 730-774), the International Traffic in Arms Regulations (22 CFR 120-130) and the various economic sanctions
regulations administered by the U.S. Department of the Treasury (31 CFR 500-600). 
 Among other
things, these laws and regulations may prohibit or require a license for the export or retransfer of certain commodities and technical data to specified countries, entities and persons. Ocean hereby gives written assurance that it will comply with,
and will cause its affiliates to comply with all United States export control laws and regulations, that it understands it may be held responsible for any violation of such laws and regulations by itself or its affiliates, and that it will
indemnify, defend and hold Stanford harmless for the consequences of any such violation. 
  

	12.	 MARKING 

Before any Licensed Patent issues, Ocean will mark Licensed Product with the words “Patent Pending.” Otherwise, Ocean will mark
Licensed Product with the number of any issued Licensed Patent. 
  

	13.	 STANFORD NAMES AND MARKS 

Ocean will not use (i) Stanford’s name or other trademarks, (ii) the name or trademarks of any organization related to Stanford,
or (iii) the name of any Stanford faculty member, employee, student or volunteer. This prohibition includes, but is not limited to, use in press releases, advertising, marketing materials, other promotional materials, presentations, case
studies, reports, websites, application or software interfaces, and other electronic media. Notwithstanding the foregoing, Ocean may include Stanford’s name in factual statements in legal proceedings, patent applications and other regulatory
filings. In addition, Ocean may make a short factual statement that identifies Stanford as the licensor of the rights granted under this Agreement to actual or potential investors or acquirers, as well as in the “About Ocean” or other
similar section of the Ocean website. 
  

	14.	 PROSECUTION AND PROTECTION OF PATENTS 

 

	14.1	 Suspected Infringement. Ocean will promptly inform Stanford of any suspected infringement of a Licensed
Patent by a third party. 

  
  

PAGE 6 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

	14.2	 Patent Prosecution. 

 

	 	(A)	 Stanford will be responsible for preparing, filing, prosecuting and maintaining the Licensed Patents.

  

	 	(B)	 In the event Ocean decides that it no longer intends to pay its prorated share for filing, prosecution, or
maintenance of one or more Licensed Patents, Ocean shall give Stanford written notice at least three (3) months in advance of any applicable deadline for that Licensed Patent. Stanford may in its discretion continue to prosecute and maintain
such Licensed Patent(s) at its expense, in which case such Licensed Patent(s) will no longer be covered by the license granted under this Agreement and Ocean will have no further obligation regarding patent expenses for such Licensed Patent(s).

  

	14.3	 Patent Costs. Within 30 days after receiving a statement from Stanford, Ocean will reimburse Stanford:

  

	 	(A)	 [####], which is pro-rated share of Licensed Patent’s prior
patenting expenses, including but not limited to interference or reexamination matters, inventorship disputes and opposition proceedings incurred by Stanford before the Effective Date; and 

 

	 	(B)	 a prorated share of all ongoing Licensed Patent’s patenting expenses, including but not limited to
interference or reexamination matters, inventorship disputes and opposition proceedings incurred by Stanford after the Effective Date. Stanford will pay the fees prescribed for large entities to the United States Patent and Trademark Office.

  

	 	(C)	 Proration will be based on an equal share of expenses to be paid by all licensees. 

 

	15.	 TERMINATION 

  

	15.1	 Termination by Ocean. Ocean may terminate this Agreement by giving Stanford written notice at least 30
days in advance of the effective date of termination selected by Ocean. 

  

	15.2	 Termination by Stanford. 

 

	 	(A)	 Stanford may also terminate this Agreement if Ocean: 

 

	 	(1)	 is not diligently developing and commercializing Licensed Product; 

 

	 	(2)	 misses a milestone described in Section 6.1 

 

	 	(3)	 is in breach of any provision; or 

 

	 	(4)	 provides any false report. 

  
  

PAGE 7 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

	 	(B)	 Termination under this Section 15.2 will take effect 30 days after written notice by Stanford unless Ocean
remedies the problem in that 30-day period. 

  

	15.3	 Surviving Provisions. Surviving any termination or expiration are: 

 

	 	(A)	 Ocean’s obligation to make all payments accrued or accruable, including but not limited to fees, royalties
and patent costs; 

  

	 	(B)	 any claim of Ocean or Stanford, accrued or to accrue, because of any breach or default by the other party; and

  

	 	(C)	 the provisions of Sections 8, 9, and 10 and any other provision that by its nature is intended to survive.

  

	16.	 CHANGE OF CONTROL, ASSIGNMENT AND NON-ASSIGNABILITY

  

	16.1	 Change of Control. If there is a Change of Control or if this Agreement is assigned to a third party,
Ocean will pay Stanford a $[####] (“Change of Control/Assignment Fee”) per Section 16.2. 

  

	16.2	 Conditions of Assignment. Ocean may assign this Agreement upon prior and complete performance of the
following conditions: 

  

	 	(A)	 Ocean must give Stanford written notice of the assignment within 5 business days, including the new
assignee’s contact information; and 

  

	 	(B)	 the new assignee must agree in writing to Stanford to be bound by this Agreement; and 

 

	 	(C)	 Stanford must have received the full Change of Control/Assignment Fee. 

Notwithstanding anything to the contrary set forth herein, the Parties hereby agree that the entry into this Amended and Restated Non-Exclusive License Agreement does not constitute an assignment under this Section 16, and no fees contemplated under this Section 16 or other amounts are owed by Ocean or OBM to Stanford. 

 

	16.3	 After the Assignment. Upon a permitted assignment of this Agreement pursuant to Section 16, Ocean
will be released of liability under this Agreement and the term “Ocean” in this Agreement will mean the assignee. 

  

	16.4	 Bankruptcy. In the event of a bankruptcy or insolvency, assignment is permitted only to a party that can
provide adequate assurance of future performance, including diligent development and sales of Licensed Product. 

  

	16.5	 Nonassignability of Agreement. Except in conformity with Section 16.2 and Section 16.4, this
Agreement is not assignable by Ocean under any other circumstances and any attempt to assign this Agreement by Ocean is null and void. 

  

	17.	 DISPUTE RESOLUTION 

 

	17.1	 Dispute Resolution by Arbitration. Any dispute between the parties regarding any payments made or due
under this Agreement will be settled by arbitration in accordance with the JAMS Arbitration Rules and Procedures, provided that in the case of a good faith dispute as to the 

  
  

PAGE 8 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

	 	
amount due, the cure period under Section 15.2 will be tolled until the amount due has been finally determined in such an arbitration. The parties are not obligated to settle any other
dispute that may arise under this Agreement by arbitration. 

  

	17.2	 Request for Arbitration. Either party may request such arbitration. Stanford and Ocean will mutually
agree in writing on a third-party arbitrator within 30 days of the arbitration request. The arbitrator’s decision will be final and nonappealable and may be entered in any court having jurisdiction. 

 

	17.3	 Discovery. The parties will be entitled to discovery as if the arbitration were a civil suit in the
California Superior Court. The arbitrator may limit the scope, time, and issues involved in discovery. 

  

	17.4	 Place of Arbitration. The arbitration will be held in Stanford, California unless the parties mutually
agree in writing to another place. 

  

	17.5	 Patent Validity. Any dispute regarding the validity of any Licensed Patent shall be litigated in the
courts located in Santa Clara County, California, and the parties agree not to challenge personal jurisdiction in that forum. 

  

	18.	 NOTICES 

  

	18.1	 Legal Action. Ocean will provide written notice to Stanford at least three months prior to bringing an
action seeking to invalidate any Licensed Patent or a declaration of non- infringement. Ocean will include with such written notice an identification of all prior art it believes invalidates any claim of the
Licensed Patent. 

  

	18.2	 All Notices. All notices under this Agreement are deemed fully given when written, addressed, and sent
as follows: 

 All general notices to Ocean are mailed or emailed to: 

 

			
	Name:	  	[####]
	Address:	  	[####]
		  	[####]
	Email:	  	[####]

 All financial invoices to Ocean (i.e., accounting contact) are e-mailed
to: 
  

			
	Name:	  	[####]
	Email:	  	[####]

 All progress report invoices to Ocean (i.e., technical contact) are
e-mailed to: 
  

			
	Name:	  	[####]
	Email:	  	[####]

 All general notices to Stanford are e-mailed or mailed to: 

  
  

PAGE 9 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

			
	 [####]
	  	
	 [####]
	  	
	 [####]
	  	
	 [####]
	  	
	 [####]
	  	

 All payments to Stanford are mailed to: 

 

			
	 [####]
	 	
	 [####]
	 	
	 [####]
	 	
	 [####]
	 	
	 [####]
	 	

 All progress reports to Stanford are e-mailed or mailed to: 

 

			
	 [####]
	  	
	 [####]
	  	
	 [####]
	  	
	 [####]
	  	
	 [####]
	  	

 Either party may change its address with written notice to the other party. 

 

	19.	 MISCELLANEOUS 

 

	19.1	 Waiver. No term of this Agreement can be waived except by the written consent of the party waiving
compliance. 

  

	19.2	 Choice of Law. This Agreement and any dispute arising under it is governed by the laws of the State of
California, United States of America, applicable to agreements negotiated, executed, and performed within California. 

  

	19.3	 Entire Agreement. The parties have read this Agreement and agree to be bound by its terms, and further
agree that it constitutes the complete and entire agreement of the parties, amends and restates the Original Agreement in its entirety, and supersedes all previous communications, oral or written, and all other communications between them relating
to the license and to the subject hereof. In the event of conflict between the terms and conditions of this Agreement and any purchase orders, the terms and conditions of this Agreement shall prevail. This Agreement may not be amended except by
writing executed by authorized representatives of both parties. No representations or statements of any kind made by either party, which are not expressly stated herein, will be binding on such party. 

 

	19.4	 Exclusive Forum. The state and federal courts having jurisdiction over Stanford, California, United
States of America, provide the exclusive forum for any court action between the parties relating to this Agreement. Ocean submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over Ocean or constitutes
an inconvenient or improper forum. 

  
  

PAGE 10 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

	19.5	 Headings. No headings in this Agreement affect its interpretation. 

 

	19.6	 Electronic Copy. The parties to this document agree that a copy of the original signature (including an
electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the
absence of an original signature. 

 The parties execute this Agreement in duplicate originals by their duly authorized
officers or representatives. 
  

							
		 	 THE BOARD OF TRUSTEES OF THE LELAND

STANFORD JUNIOR UNIVERSITY
	 	
				
		 		 	                                      
                                         
 	 	
				
		 	Signature:	 	                                      
                                  	 	
				
		 	Name:	 	                                      
                                  	 	
				
		 	Title:	 	                                      
                                  	 	
				
		 	Date:	 	                                      
                                  	 	

  

							
		 	OCEAN PROMISE, INC.	 	
				
		 	Signature:	 	                                      
              	 	
				
		 	Name:	 	                                      
              	 	
				
		 	Title:	 	                                      
              	 	
				
		 	Date:	 	                                      
              	 	

  
  

PAGE 11 OF 12 

					
		  	 AMENDED AND RESTATED NONEXCLUSIVE LICENSE

AGREEMENT
	  	
	S20-122: MW	  	 	  	6/25/2020

  

 Appendix A – Progress Report 

Sent by email to Stanford OTL at finance@otlmail.stanford.edu and info@otlmail.stanford.edu for the calendar year XXXX, pursuant to paragraph
6.2 of the Amended and Restated Non-Exclusive License Agreement for Covid-19 Related Technology (“License Agreement”) between Stanford University and Ocean,
effective March 3, 2021 
  

	 	A.	 List all Stanford dockets currently covered by the License Agreement. State whether any dockets have
been added or dropped from the agreement in the past year. 

  

	 	B.	 Summarize progress made with Licensed Product during the past year (2-4
paragraphs), including: work completed, key scientific discoveries, ongoing work-in-progress, plans for introducing Licensed Product to market, other relevant
information. 

  

	 	C.	 Status of Diligence Milestones that came due in the past year (per Section 6.1 / Appendix A of License
Agreement). Use format below; bold text indicates required info. Add rows to table as needed. 

  

			
	 Milestone
	  	 Status

	     

By                         
                       , 20XX
  

Milestone # [    ] from License Agreement:
	  	 Completed / Not Completed [brief description of status and relevant dates]

 
 Completed.

[OR]
 Not completed.

	     

By                         
                       , 20XX
  

Milestone # [    ] from License Agreement:
	  	 Completed / Not Completed [brief description of status and relevant dates]

 
 Completed.

[OR]
 Not Completed.

  

	 	D.	 Describe any significant corporate transactions during the past year. 

 

	 	E.	 Describe future plans, including estimated total development time remaining before Licensed Product will be
commercialized. 

  

	 	F.	 Update company contacts for progress reports, patent prosecution and financial information, if needed.

  
  

PAGE 12 OF 12Exhibit 4.4

 

 

 

 

 

 

	Amended
                                            and Restated Convertible Note Deed	 

 

Wize Pharma, Inc.

 

The Noteholders

 

 

 

 

 

 

 

 

 

 

 

77 Castlereagh Street

Sydney NSW 2000

Australia

 

	T	+61 2 9931 4999

	F	+61 2 9931 4888

	Ref	JRE:40043060

 

     

     

    

 

Contents

 

	1.	Definitions and interpretation	1
	 	 	 
	2.	Issue of Convertible Notes	5
	 	 	 
	3.	Convertible Note Certificates	5
	 	 	 
	4.	Status of Convertible Notes	5
	 	 	 
	5.	Register	6
	 	 	 
	6.	Discharge and release	7
	 	 	 
	7.	Payments	7
	 	 	 
	8.	Warranties	7
	 	 	 
	9.	Covenants	9
	 	 	 
	10.	Notices	10
	 	 	 
	11.	Waiver	11
	 	 	 
	12.	Invalidity	11
	 	 	 
	13.	Variation	11
	 	 	 
	14.	Governing law	11
	 	 	 
	Schedule 1 - Convertible Note Certificate	13
	 	 
	Schedule 2 - Conditions	15

 

    i

     

    

 

Amended and Restated Convertible
Note Deed

 

Dated 9 March 2021

 

Parties

 

	1.	Wize Pharma, Inc. of c/- Level 5, 97 Pacific Highway, North Sydney NSW 2060 Australia (Company).

 

	2.	The holders of Convertible Notes created and issued by the Company in accordance with clause 16 of the Original Deed (Noteholders).

 

Background

 

	A.	Cosmos borrowed money from the Noteholders through the issue of convertible notes under the Original Deed.

 

	B.	In accordance with clause 16 of the Original Deed, as of the Effective Date Cosmos has ceased to be a party to this deed, the Company
has become a party to this deed and the Company has become indebted to the Noteholders in the amount of the Amount Outstanding and has
issued the Convertible Notes to the Noteholders subject to the terms and conditions of this deed.

 

Operative provisions

 

	1.	Definitions and interpretation

 

	1.1	Definitions

 

The following definitions apply unless the context requires
otherwise.

 

Amount Outstanding means, in
relation to Convertible Notes, the Face Value of the Convertible Notes together with all Interest accrued on the Convertible Notes, which
as at the Issue Date is equal to the USD Amount Outstanding.

 

Board means the board of directors of the Company
as constituted from time to time.

 

Business Day means a day on which trading banks are
open for general banking business in Delaware, United States excluding Saturday, Sunday and any public holiday in Delaware, United States.

 

Conditions means the conditions
of issue of the Convertible Notes specified in Schedule 2 and Condition means one of them.

 

Constitution means the Company’s
certificate of incorporation, certificates of designation and bylaws, as amended from time to time.

 

    1

     

    

 

Conversion means, in relation
to Convertible Notes, the redemption of the Convertible Notes by repayment of the Amount Outstanding and the simultaneous application
of the Amount Outstanding in subscribing for Shares, and Convert and Converted have corresponding meanings.

 

Conversion Date means the earlier of:

 

		(a)	the date that is six months after the Original Issue Date; and

 

		(b)	the date of completion of a Qualified Financing.

 

Convertible Note Certificate means,
in relation to Convertible Notes, a certificate in the form of Schedule 1 relating to those Convertible Notes that are issued in accordance
with the terms and conditions of this deed.

 

Convertible Notes means the
convertible notes of the Face Value issued by the Company in accordance with clause 2 of this deed.

 

Cosmos means Cosmos Capital Limited ACN 636 458
912.

 

Effective Date has the meaning given in the Original
Deed.

 

Face Value means, in relation
to each Convertible Note, the amount of $0.77.

 

Immediately Available Funds means by bank cheque or an electronic transfer of funds.

 

Insolvency Event means the occurrence of any one or more of the following:

 

		(a)	the Company applies for, consents to, or acquiesces in, the appointment of a trustee, receiver or other custodian for the Company,
or a substantial part of its assets, or makes a general assignment for the benefit of its creditors;

 

		(b)	the Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other
law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes
any corporate action in furtherance of any of the foregoing;

 

		(c)	an involuntary petition is filed against the Company (unless such petition is dismissed or discharged within 60 days under any bankruptcy
statute now or hereafter in effect or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official)
is appointed to take possession, custody or control of any property of the Company or

 

		(d)	a resolution being passed by the persons necessary to approve the dissolution and winding up of the Company.

 

Interest means interest calculated in accordance
with Condition 2.

 

Interest Rate means a rate of 8% per annum.

 

Issue Date means the Effective Date.

 

Noteholder means a person whose
name is entered in the Register as the holder of a Convertible Note or Convertible Notes.

 

Original Deed means the deed
dated 8 February 2021 by Cosmos in favour of the Noteholders, of which this deed is as amended and restated in accordance with clause
16 of the Original Deed.

 

Original Issue Date means the
Issue Date as defined in, and in respect of the issue of convertible notes under, the Original Deed.

 

    2

     

    

 

Qualified Financing means the admission of the
Company’s shares to quotation on the NASDAQ Stock Market.

 

Register means the register
of Convertible Notes maintained by the Company pursuant to clause 5.

 

Redemption Date means the date of the occurrence
of an Insolvency Event.

 

Redeemed means redeemed in accordance with Condition
6 and Redemption and Redeem have corresponding meanings.

 

Share means a share of common stock in the capital
of the Company.

 

United States or US means the
United States of America, its territories and possessions, any state of the United States, and the District of Columbia.

 

U.S. person means (i) any natural person resident
in the United States; (ii) any partnership or corporation organized or incorporated under the laws of the United States; (iii) any estate
of which any executor or administrator is a U.S. person; (iv) any trust of which any trustee is a U.S. person; (v) any agency or branch
of a foreign entity located in the United States; (vi) any non-discretionary account or similar account (other than an estate or trust)
held by a dealer or other fiduciary for the benefit or account of a U.S. person; (vii) any discretionary account or similar account (other
than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States;
and (viii) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed
by a U.S. person principally for the purpose of investing in securities not registered under the US Securities Act, unless it is organized
or incorporated, and owned, by accredited investors (as defined in Rule 501(a) promulgated under the US Securities Act) who are not natural
persons, estates or trusts. The following are not “U.S. persons”: (i) any discretionary account or similar account (other
than an estate or trust) held for the benefit or account of a non-U.S. person by a dealer or other professional fiduciary organized,
incorporated, or (if an individual) resident in the United States; (ii) any estate of which any professional fiduciary acting as executor
or administrator is a U.S. person if: (A) an executor or administrator of the estate who is not a U.S. person has sole or shared investment
discretion with respect to the assets of the estate; and (8) the estate is governed by foreign law; (iii) any trust of which any professional
fiduciary acting as trustee is a U.S. person, if a trustee who is not a U.S. person has sole or shared investment discretion with respect
to the trust assets, and no beneficiary of the trust (and no settler if the trust is revocable) is a U.S. person; (iv) an employee benefit
plan established and administered in accordance with the law of a country other than the United States and customary practices and documentation
of such country; (v) any agency or branch of a U.S. person located outside the United States if: (A) the agency or branch operates for
valid business reasons; and (B) the agency or branch is engaged
in the business of insurance or banking and is subject to substantive insurance or banking regulation, respectively, in the jurisdiction
where located; and (vi) The International Monetary Fund, the International Bank for Reconstruction and Development, the Inter-American
Development Bank, the Asian Development Bank, the African Development Bank, the United Nations, and their agencies, affiliates and pension
plans, and any other similar international organizations, their agencies, affiliates and pension plans.

 

US Securities Act means the United States Securities
Act of 1933.

 

USD Amount Outstanding has the meaning given in clause
16.3(c) of the Original Deed.

 

VWAP means volume-weighted average price.

 

    3

     

    

 

	1.2	Interpretation

 

In this deed, unless the context requires otherwise:

 

		(a)	the singular includes its plural and vice versa;

 

		(b)	words denoting any gender include all genders;

 

		(c)	where a word or phrase is defined, its other grammatical forms have a corresponding meaning;

 

		(d)	headings are for convenience only and do not affect interpretation;

 

		(e)	a reference to a person includes a corporation, trust, partnership, unincorporated body or other entity, whether or not it comprises
a separate legal entity;

 

		(f)	a reference to a party to this deed includes its successors and permitted assigns;

 

		(g)	a reference to a particular day or time is to that day or time in Delaware, United States;

 

		(h)	a reference to any agreement (including this deed) or document is to the agreement or document as amended, supplemented, novated or
replaced from time to time;

 

		(i)	a reference to a clause, paragraph, schedule or annexure is to a clause, paragraph, schedule or annexure in or to this deed;

 

		(j)	a reference to this deed includes any schedules and annexures
to this deed;

 

		(k)	a reference to writing includes any method of representing or reproducing words, figures, drawings or symbols in a visible or tangible
form;

 

		(I)	a reference to $ or USD is to the currency of the United
                                            States;

 

		(m)	a reference to legislation (including subordinate legislation) or a provision of it is to that legislation
or provision as amended, re-enacted or replaced, and includes any subordinate legislation issued under it;

 

		(n)	words such as including or for example do not limit the
                                            meaning of the words preceding them (i.e., including shall be read as “including without
                                            limitation”);

 

		(o)	an obligation or liability assumed by, or a right conferred on, two or more parties binds or benefits all of them jointly and each
of them severally; and

 

		(p)	nothing in this deed is to be interpreted against a party solely on the ground that the party or its advisers drafted it.

 

	1.3	Business Days

 

If the day on or by which a person
must do something under this deed is not a Business Day:

 

		(a)	if the act involves a payment that is due on demand, the person must do it on or by the next Business
Day; and

 

		(b)	in any other case, the person must do it on or by the next Business Day.

 

    4

     

    

 

	2.	Issue of Convertible Notes

 

On the
Issue Date, and subject to Wize having sufficient authorised capital, Wize must issue to each Noteholder the number of Convertible Notes,
each having the Face Value, equal to the USD Amount Outstanding in respect of that Noteholder divided by the Face Value (and if the calculation
results in an entitlement to a fraction of a Convertible Note, the number of Convertible Notes will be rounded down to the nearest whole
number), subject to and in accordance with this deed.

 

	3.	Convertible Note Certificates

 

	3.1	Issue

 

The Company must issue a Convertible Note Certificate to
each person who is issued a Convertible Note within 10 Business Days after the Issue Date of that Convertible Note.

 

	3.2	Note Conditions of Issue

 

The Conditions are deemed to be included or endorsed on
each Convertible Note Certificate.

 

	3.3	Replacement

 

If a Convertible Note Certificate
becomes worn out or defaced, then on production of the Convertible Note Certificate to the Company, the Company must cancel it and issue
a replacement Convertible Note Certificate.

 

	3.4	Missing Certificate

 

If a Convertible Note Certificate
is lost or destroyed, the Company must issue a duplicate Convertible Note Certificate in its place on application in writing by the Noteholder
accompanied by the following:

 

		(a)	a statutory declaration or such other evidence as the Company may reasonably require that:

 

		(i)	the Convertible Note Certificate has been lost or destroyed; and

 

		(ii)	if the Convertible Note Certificate has been lost, proper searches for it have been made;

 

		(b)	a written undertaking that if the original Convertible Note Certificate is found or received by the Noteholder, it will be returned
to the Company; and

 

		(c)	any indemnity required by the Company.

 

	4.	Status of Convertible Notes

 

	4.1	Ranking

 

Each Convertible Note:

 

		(a)	ranks equally with each other Convertible Note; and

 

		(b)	is held subject to and with the benefit of the terms and conditions of this deed (including the Conditions).

 

    5

     

    

 

	4.2	Conditions

 

The Convertible Notes are issued on
condition that the Company is bound by, and complies with, the terms and conditions of this deed (including the Conditions).

 

	4.3	Rights

 

The Company acknowledges and confirms
in favour of the Noteholders that the obligations imposed on the Company under this document in relation to the Convertible Notes issued
by the Company are owed to and are for the benefit of each Noteholder from time to time so that each Noteholder has the benefit of, and
may, subject to the terms of this deed, enforce, this document against the Company even though it is not party to, or is not in existence
at the time of execution and delivery of, this deed.

 

	4.4	Unsecured

 

The Convertible Notes are unsecured obligations of the Company.

 

	4.5	No rights or liabilities as shareholders

 

In the absence of conversion of a Convertible Note, no provisions
of such Convertible Note, Convertible Note Certificate or this deed, and no enumeration herein of the rights or privileges of the Noteholder,
shall cause such Noteholder to be a stockholder of the Company for any purpose. Prior to conversion of a Convertible Note, the Noteholder
shall not be entitled to any rights of a stockholder with respect to any Shares into which such Convertible Note might convert, including
(without limitation) the right to vote such Shares, receive distributions thereon, exercise pre-emptive rights or be notified of meetings,
and the Noteholder shall not be entitled to any notice or other communication concerning the business or affairs of the Company.

 

	5.	Register

 

	5.1	Company must keep Register

 

The Company must establish and keep the Register which
must record:

 

		(a)	the name and address of each Noteholder;

 

		(b)	the number of Convertible Notes held by each Noteholder;

 

		(c)	the Issue Date or date of transmission of Convertible Notes held by each Noteholder; and

 

		(d)	particulars of any Conversion or Redemption of Convertible Notes held by each Noteholder.

 

	5.2	Holder

 

A person whose name is entered in
the Register in respect of Convertible Notes is the holder of those Convertible Notes. An entry in the Register is conclusive evidence
that the person named in the entry is the absolute owner of, and holder of title to, the Convertible Notes registered in the name of that
person.

 

    6

     

    

 

	5.3	Certificates

 

A
Convertible Note Certificate relating to Convertible Notes is prima facie evidence that the person named in the Convertible Note
Certificate as the holder of the Convertible Notes is the owner of, and holder of title to, the Convertible Notes. Convertible Note
Certificates, and any certificate representing Shares into which a Convertible Note is converted, will be issued with a legend in
compliance with securities laws substantially similar to the following:

 

“THIS CERTIFICATE AND THE SECURITIES
ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER
THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT
AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.
THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER,
PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS UNLESS SUCH SALE OR TRANSFER IS PURSUANT
TO RULE 144 UNDER THE ACT.”

 

	6.	Discharge and release

 

The Company is immediately discharged
and released from its liabilities, obligations and covenants under this deed in respect of any Convertible Note on the first to occur
of:

 

		(a)	the date on which that Convertible Note and all Interest on that Convertible Note is Redeemed and paid in accordance with the Conditions;
and

 

		(b)	the date on which that Convertible Note and all Interest on that Convertible Note is Converted in accordance with the Conditions,

 

whether or not the Convertible Note
Certificate with respect to such Convertible Notes has been surrendered or delivered to the Company.

 

	7.	Payments

 

	7.1	Payments

 

Except as specifically set out in this
deed (including the Conditions), the Company must pay each amount required to be paid by it under this deed (including the Conditions)
in Immediately Available Funds free of any costs, charges or expenses.

 

	7.2	No Set Off

 

The Company has no right to set off,
counterclaim or otherwise deduct from or withhold any payment that it is liable to make to a Noteholder under this deed (including the
Conditions) against any money that the Noteholder is or may be liable to pay to the Company, whether under this deed or otherwise.

 

	8.	Warranties

 

	8.1	Warranties by the Company

 

The Company warrants to each Noteholder as at the Issue
Date that:

 

		(a)	(status) it is validly existing and in good standing under the laws of the place of its incorporation or creation;

 

    7

     

    

 

		(b)	(power) it has the power to enter into and perform its obligations under this deed (including the Conditions), to carry
out the transactions contemplated by this deed (including the Conditions) and to carry on its business as now conducted or contemplated;

 

		(c)	(corporate authorisations) it has taken all necessary action to authorise the entry into and performance of this deed and to
carry out the transactions contemplated by this deed;

 

		(d)	(documents binding) this deed (including the Conditions) create valid and binding obligations on it enforceable in accordance
with their terms, subject to any necessary stamping and registration; and

 

		(e)	(transactions permitted) the execution and performance by it of this deed and each transaction contemplated under this deed
did not and will not violate in any respect a provision of:

 

		(i)	a law or treaty or a judgment, ruling, order or decree of a government or governmental authority or agency binding on it; or

 

		(ii)	its constitution, deeds establishing the existing trusts or other constituent documents.

 

	8.2	Warranties and acknowledgements by the Noteholders

 

Each Noteholder warrants to the Company as at the Issue
Date that:

 

		(a)	(purchase entirely for own account) each Convertible Note and the Shares issuable upon conversion of the Convertible Note (collectively,
the “Securities”) are and will be acquired for investment for the Noteholder’s own account, not as a nominee or agent,
and not with a view to the resale or distribution of any part thereof, and that the Noteholder has no present intention of selling, granting
any participation in, or otherwise distributing the same;

 

		(b)	(disclosure of information; non-reliance) the Noteholder has received all the information it considers necessary or appropriate
to enable it to make an informed decision concerning an investment in the Securities. The Noteholder has had an opportunity to ask questions
and receive answers from the Company regarding the terms and conditions of the offering of the Securities. The Company has not given any
guarantee or representation as to the potential success, return, effect or benefit (either legal, regulatory, tax, financial, accounting
or otherwise) of an investment in the Securities. In deciding to purchase the Securities, the Noteholder is not relying on the advice
or recommendations of the Company and has made its own independent decision that the investment in the Securities is suitable and appropriate
for the Noteholder. No federal or state agency has passed upon the merits or risks of an investment in the Securities or made any finding
or determination concerning the fairness or advisability of this investment;

 

		(c)	(accredited investor) the Noteholder is an “accredited investor” within the meaning of Rule 501 of Regulation D promulgated
under the US Securities Act;

 

		(d)	(no general solicitation) neither the Company nor any other person offered to sell the Securities to it by means of any form
of general solicitation or advertising within the meaning of Rule 502 of Regulation D under the US Securities Act or in any manner involving
a public offering within the meaning of Section 4(a)(2) of the US Securities Act;

 

    8

     

    

 

		(e)	(foreign investors) it has satisfied itself as to
the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Securities, including (a)
the legal requirements within its jurisdiction for the purchase of the Securities; (b) any foreign exchange restrictions applicable
to such purchase; (c) any governmental or other consents that may need to be obtained; and (d) the income tax and other tax consequences,
if any, that may be relevant to the purchase, holding, conversion, redemption, sale, or transfer of the Securities. The Noteholder’s
subscription and payment for and continued beneficial ownership of the Securities will not violate any applicable securities or other
laws of the Noteholder’s jurisdiction. The Company has taken no action in foreign jurisdictions with respect to the Securities;
and

 

		(f)	(non-US person) it is not a U.S. person and, in connection therewith, that: (i) as at the Issue Date the Noteholder was outside
the United States; (ii) the Noteholder is acquiring the Securities for its own account, for investment and not for distribution or resale
to others and not for the account or benefit of any U.S. person, or with a view towards distribution to any U.S. person.

 

Each Noteholder also acknowledges that
the Securities have not been, and will not be, registered under the US Securities Act or state securities laws, by reason of specific
exemptions from the registration provisions thereof which depend upon, among other things, the bona fide nature of the investment intent
and the accuracy of the Noteholder’s representations as expressed herein. The Securities are “restricted securities” under U.S.
federal and applicable state securities laws and that, pursuant to these laws, the Noteholder must hold the Securities indefinitely unless
they are registered with the Securities and Exchange Commission (“SEC”) and registered or qualified by state authorities, or
an exemption from such registration and qualification requirements is available. The Company has no obligation to register or qualify
the Securities for resale and the Noteholder further acknowledges that, if an exemption from registration or qualification is available,
it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Securities,
and on requirements relating to the Company which are outside of the Noteholder’s control, and which the Company is under no obligation,
and may not be able, to satisfy.

 

	9.	Covenants

 

The Company must, subject to and in
accordance with the terms and conditions of this deed (including the Conditions):

 

		(a)	comply with the Conditions;

 

		(b)	accrue Interest on the Convertible Notes in accordance with the Conditions;

 

		(c)	as and when Convertible Notes are due to be Redeemed, Redeem them and pay the Face Value in respect of them, together with any accrued
Interest and all other amounts that are payable to the Noteholders in accordance with the terms and conditions of this deed (including
the Conditions);

 

		(d)	as and when Convertible Notes are Converted, Convert them and apply the funds as consideration for the issue of Shares in accordance
with the Conditions; and

 

		(e)	execute and do all things necessary to give effect to this deed (including the Conditions) and the Convertible Notes and to confer
the full benefit of them on Noteholders.

 

    9

     

    

 

	10.	Notices

 

	10.1	How notice to be given

 

Each communication (including each
notice, consent, approval, request and demand) under or in connection with this deed:

 

		(a)	may be given by personal service, post or email;

 

		(b)	must be in writing and in English;

 

		(c)	must be addressed as follows (or as otherwise notified by that party to the other party from time to time):

 

		(i)	if to the Company:

 

		Address:	Level 5, 97 Pacific Highway 

North Sydney NSW 2060

 Australia

 

		Email:	james@cosmoscapital.io

 

		(ii)	if to a Noteholder, at the address set out in the Register

 

		(d)	(in the case of personal service or post) must be signed by the party making it or (on that party’s behalf) by the solicitor for,
or any attorney, director, secretary or authorised agent of, that party;

 

		(e)	(in the case of email) must be pdf or other non-editable format and be attached to an email that states that the attachment is a communication
under this deed; and

 

		(f)	must be delivered by hand or posted by prepaid certified or registered post to the address, or sent by email with a read receipt requested
to the email address, of the addressee, in accordance with subclause (c).

 

	10.2	When notice taken to be received

 

Each communication (including each
notice, consent, approval, request and demand) under or in connection with this deed is taken to be received by the addressee:

 

		(a)	(in the case of prepaid post sent to an address in the same country) on the third Business Day after the date of posting;

 

		(b)	(in the case of prepaid post sent to an address in another country) on the fifth Business Day after the date of posting by airmail;

 

		(c)	(in the case of delivery by hand) on delivery; and

 

		(d)	(in the case of email) unless the party sending the email knows or reasonably ought to suspect that the email and the attached communication
were not delivered to the addressee’s domain specified in the email address notified for the purposes of clause 10.1, the earlier of the
time specified in a read receipt received from the addressee and 24 hours after the email was sent provided that no notice has been received
in that period indicating that the email has not been successfully delivered.

 

but if the communication would otherwise
be taken to be received on a day that is not a Business Day or after 5.00 pm, it is taken to be received at 9.00 am on the next Business
Day.

 

    10

     

    

 

	11.	Waiver

 

Failure to exercise or enforce or a
delay in exercising or enforcing or the partial exercise or enforcement of any right, power or remedy provided by law or under this deed
(including the Conditions) by any party will not in any way preclude, or operate as a waiver of, any exercise or enforcement, or further
exercise or enforcement of that or any other right, power or remedy provided by law or under this deed (including the Conditions). Any
waiver or consent given by any party under this deed (including the Conditions) will only be effective and binding on that party if it
is given or confirmed in writing by that party. No waiver of a breach of any term of this deed (including the Conditions) will operate
as a waiver of another breach of that term or of a breach of any other term of ttiis deed (including the Conditions).

 

	12.	Invalidity

 

Any provision of this deed that is
invalid or unenforceable in any jurisdiction is, as to that jurisdiction, only to be read down or severed to the extent of that invalidity
or unenforceability so long as the remaining provisions of this deed are properly and effectively self-sustaining and capable of separate
enforcement without regard to the read down or severed provision in that jurisdiction. The remaining provisions continue to be valid and
enforceable in accordance with their terms.

 

	13.	Variation

 

	13.1	Variation by Board

 

The Board may, by resolution, vary,
modify, alter, cancel, amend or add to all or any of this deed or the Conditions if in their opinion the modification, alteration, cancellation,
amendment or addition is:

 

		(a)	of a formal or technical nature;

 

		(b)	made to correct a manifest error; or

 

		(c)	necessary to comply with the provisions of any statute or the requirements of any statutory authority.

 

	13.2	Other Variations

 

Subject to clause 13.1, this deed and
the Conditions may only be varied by a document signed by the Company and by the Noteholders holding a majority-in-interest of the aggregate
principal amount of the Convertible Notes. Any amendment effected in accordance with this clause 13.2 will be binding upon each Noteholder.

 

	14.	Governing law

 

This deed (including the Conditions)
is governed by the law in force in the State of Delaware, United States and each party submits to the non-exclusive jurisdiction of the
courts of that State in relation to all matters arising under this deed (including the Conditions).

 

    11

     

    

 

Signing page

 

Executed as a deed.

 

	Executed by Wize Pharma, Inc.	 
	 	 	 
	By:	/s/ James Manning	 
	Name: 	James Manning	 
	Title:	DIRECTOR	 

 

    12

     

    

 

Schedule 1 – Convertible Note Certificate

 

 

THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON THE
CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED
EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN
EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT
SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS
UNLESS SUCH SALE OR TRANSFER IS PURSUANT TO RULE 144 UNDER THE
ACT.

 

Location of Register: Delaware, United States

 

Certificate Number:

 

This is to certify that:

 

The person named
in Item 1 of the Schedule is the holder of that number of Convertible
Notes as is specified in Item 2 of the Schedule.

 

Each Convertible Note has a Face Value
as specified in Item 3 of the Schedule. The aggregate Face Value for all of the Convertible Notes is as specified in Item 4
of the Schedule.

 

The Convertible Notes are paid in full.

 

The Convertible
Notes certified by this Convertible Note Certificate are issued on the date specified in Item 5 of the Schedule on and subject to the
Conditions, a copy of which is attached.

 

In this certificate,
a reference to a Convertible Note means a Convertible Note issued under clause 2 of the Amended and Restated Convertible Note Deed dated
9 March 2021 by Wize Pharma, Inc., in favour of the Noteholders (Convertible Note Deed).

 

	Executed by Wize Pharma, Inc.	 
	 	           	 
	By:	                	 
	Name: 	 	 
	Title:	 	 

 

The Noteholder is bound by the Conditions attached to this
Certificate.

 

    13

     

    

 

SCHEDULE TO CONVERTIBLE NOTE CERTIFICATE

 

	Item 1	Name
	Noteholder	 
	 	ABN
	 	 
	 	Address
	 	 
	Item 2	 
	Number of Notes	[ ]
	 	 
	Item 3	 
	Face Value of each Note	$0.77
	 	 
	ltem4	 
	Aggregate Face Value of Notes	[$#]
	 	 
	Item 5	 
	Issue Date	9 March 2021

 

    14

     

    

 

Schedule 2 – Conditions

 

 

	1.	General Terms of Issue

 

	1.1	Capitalised terms in these Conditions have the meanings given to them in the Convertible Note Deed.

 

	1.2	Each Convertible Note:

 

		(a)	is issued at its Face Value;

 

		(b)	bears interest under Condition 2;

 

		(c)	is convertible into Shares in the manner and at the times provided by Conditions 3 and 4;

 

		(d)	is redeemable in accordance with Condition 6; and

 

		(e)	is not transferrable.

 

	1.3	The Company will execute all documents and take all actions reasonably required to comply with these Conditions.

 

	2.	Interest

 

	2.1	Each Convertible Note will bear simple Interest from the Issue Date at the Interest Rate. Interest will be calculated on the principal
from and including the Issue Date until and including the date of Conversion or Redemption. If the date of Conversion or Redemption occurs
less than six months after the Original Issue Date, then Interest will be calculated on the principal from and including the Issue Date
until and including the date that is six months after the Original Issue Date

 

	2.2	Accrued Interest will be paid to the Noteholder on the Redemption Date. On the Conversion Date, accrued Interest will either (at the
Company’s election in its entire discretion, provided that the Company must make the same election in respect of all Noteholders) be paid
to the Noteholder or Converted into Shares, the number of Shares to be calculated in accordance with the following formula:

 

S = Al / P

 

where:

 

S is the number of Shares;

 

Al is the accrued Interest; and

 

P is the issue price of Shares under
the Qualified Financing or the VWAP of Shares over the 7 days prior to the Conversion Date, whichever is lower.

 

If the calculation results in an entitlement
to a fraction of a Share, the number of Shares will be rounded down to the nearest whole number.

 

	2.3	On Conversion of a Convertible Note, the obligation of the Company to pay Interest in respect of the Convertible Note after the Conversion
is extinguished.

 

    15

     

    

 

	3.	Automatic Conversion

 

	3.1	On the Conversion Date, each Convertible Note will automatically convert into 2.27138643 Shares.

 

	3.2	If the calculation under Condition 3.1 (in respect of the conversion of all of the Convertible Notes of a Noteholder) results in an
entitlement to a fraction of a Share, the number of Shares will be rounded down to the nearest whole number.

 

	4.	Issue of Shares on Conversion

 

	4.1	On the Conversion Date the Company must allot and issue to the Noteholder the Shares to which the Noteholder is entitled in respect
of that Conversion.

 

	4.2	All Shares issued to a Noteholder on Conversion of Convertible Notes must be issued by the Company fully paid.

 

	4.3	The Shares issued on Conversion under Condition 3 will rank equally in all respects with the existing Shares issued by the Company
at the Conversion Date.

 

	4.4	All Shares issued to a Noteholder on Conversion of the Convertible Notes must be held by the Noteholder on and subject to the terms
and conditions of the Constitution.

 

	4.5	The Noteholder must deliver to the Company the Certificates relating to any Convertible Notes prior to Conversion of the Convertible
Notes.

 

	4.6	The certificate in respect of any Shares issued to a Noteholder on Conversion of the Convertible Notes may bear the following or a
similar legend:

 

THIS INSTRUMENT AND THE SECURITIES TO
WHICH IT RELATES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED
FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR UPON
RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT OR UNLESS
SOLD PURSUANT TO RULE 144 UNDER THE ACT.

 

	5.	Reorganisation

 

Where as a consequence of:

 

		(a)	a pro rata bonus issue of Shares (not including an issue for cash or other consideration);

 

		(b)	a subdivision or consolidation of Shares; or

 

		(c)	any other reorganisation of share capital,

 

(each a Reorganisation Event) the
number of Shares alters, then the number of Shares into which the Convertible Notes are convertible is adjusted so that the Convertible
Notes are convertible into the same percentage of the issued share capital as the percentage into which they are convertible immediately
before the relevant Reorganisation Event.

 

    16

     

    

 

	6.	Redemption

 

	6.1	The Company may not redeem or repay the Convertible Notes other than in accordance with this Condition 6.

 

	6.2	On the Redemption Date the Company must redeem all Convertible Notes and the Company must pay to the Noteholders the Amount Outstanding
as at the Redemption Date.

 

	6.3	On Redemption, each Noteholder must deliver to the Company the Convertible Note Certificates relating to the Convertible Notes held
by the Noteholders that are being Redeemed.

 

	7.	General

 

	7.1	Property in a Convertible Note will for all purposes be regarded as situated at the place where the Register on which the Convertible
Note is for the time being registered situated and not elsewhere.

 

	7.2	Subject to the other Conditions, the Company will recognise the Noteholder of Convertible Notes as the absolute owner of the Convertible
Notes.

 

	7.3	The legal personal representatives of a deceased Noteholder (not being one of several joint Noteholders) are the only persons recognised
by the Company as having any title to the Convertible Notes registered in the name of that Noteholder.

 

	7.4	Subject to the Convertible Note Deed, the other Conditions and except as ordered by a court of competent jurisdiction or by law, the
Company is not bound to take notice of or enter in the Register any trust or equity affecting the ownership of Convertible Notes or any
incidental rights, and the receipt by any Noteholder or the legal personal representatives of a deceased Noteholder of any money payable
in respect of the Notes is a good discharge to the Company.

 

	7.5	Subject to the provisions of these Conditions relating to transfers, any person becoming entitled to Convertible Notes as a consequence
of the liquidation, death, insolvency or other demise of a Noteholder may, on producing such evidence of that person’s title as the Company
considers sufficient, be registered as the Noteholder.

 

	7.6	Subject to the other Conditions, if several persons are entered in the Register as the joint Noteholders of any Convertible Notes
then the payment to any one of those persons of the Face Value and interest from time to time payable in respect of the Convertible Notes
will be an effective discharge to the Company for the money so paid and notice to any one of those persons will be an effective notice
to all of those persons.

 

	7.7	In the case of the death of any one of joint Noteholders, the survivor or survivors are the only person
or persons recognised by the Company as having any title or interest in the Convertible Notes registered in their names jointly.

 

	7.8	Time is of the essence of the Company’s obligations under these Conditions unless otherwise agreed in writing by the Noteholders.

 

 

17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]